Meet the faculty
Sabina Berezowska
Chief Physician, Pulmonary Pathology, Lausanne University Hospital; Associate Professor of Pathology, University of Lausanne, Switzerland
Dr. Sabina Berezowska completed her medical degree and doctorate at the Technical University of Munich, followed by pathology training in Munich and Bern. She was a visiting scholar in thoracic pathology at the University of Michigan and has held leadership roles in lung pathology at the University of Bern and CHUV.
Her clinical and research expertise includes thoracic tumor pathology, digital pathology, and biomarker stratification in lung cancer. Dr. Berezowska is an active contributor to international thoracic pathology initiatives and currently chairs the Pulmonary Pathology Working Group of the European Society of Pathology. She serves on the IASLC Pathology Committee and co-authored the chapter on HER2 in the IASLC Atlas of Molecular Testing in Lung Cancer. Her work is widely published and supported by national and international research grants.
Disclosures:
Honoraria/advisory boards (fees to institutions): AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Merck, MSD
Stevan Bradford
Patient, USA
Stevan has worked in the industrial field for many years and is currently a shift coordinator at a steel mill, overseeing acid regeneration operations. He’s passionate about the outdoors and enjoys spending time in state parks, hiking, boating, fishing, and photography. His favourite quote is Emerson’s “In the woods we return to reason and faith”, which reflects his deep connection to nature and resilience through life’s challenges.
Disclosures
Nothing to disclose.
Alexander Drilon
Chief, Early Drug Development,
Memorial Sloan Kettering Cancer Center, New York, USA
Dr. Alexander Drilon is the Chief of the Early Drug Development Service and an Associate Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York. His research focuses on the development of targeted therapy for genomic subsets of lung cancer and other solid tumors, including cancers that harbor fusions involving ALK, ROS1, RET, and NTRK1/2/3, and MET exon 14 skipping alterations. He is a recipient of American Society for Clinical Oncology (ASCO)/Conquer Cancer Foundation Career Development and Young Investigator Awards, and grants from the International Association for the Study of Lung Cancer and the Lung Cancer Research Foundation. Dr. Drilon is also a member of the Editorial Board of ASCO University.
Disclosures:
Honoraria/advisory boards: Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem, MORE Health, Abbvie, 14ner/Elevation Oncology, ArcherDX, Monopteros, Novartis, EMD Serono, Medendi, Repare RX, Nuvalent, Merus, Chugai Pharmaceutical, Remedica Ltd, mBrace, AXIS, EPG Health, Harborside Nexus, Liberum, RV More, Ology, Amgen, TouchIME, Janssen, Entos, Treeline Bio, Prelude, Applied Pharmaceutical Science, Inc, AiCME, I3 Health, MonteRosa, Innocare, Boundless Bio
Equity: Treeline Bio
Associated research paid to institution: Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar
Copyright: Selpercatinib-Osimertinib (filed/pending)
Research: Foundation Medicine
Royalties: Wolters Kluwer
Other (food/beverage): Merck, Puma, Merus, Boehringer Ingelheim
CME honoraria: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD, MJH Life Sciences, Med Learning, Imedex, Answers in CME, Clinical Care Options, EPG Health, JNCC/Harborside, Liberum, Remedica Ltd., Lungevity.
Program Director
Justin Gainor, MD
Assistant Professor of Medicine, Harvard Medical School
Director, Center for Thoracic Cancers, Massachusetts General Hospital
Director, Targeted Immunotherapy, Henri and Belinda Termeer Center for Targeted Therapies
Dr. Justin Gainor is a thoracic medical oncologist and Director of the Center for Thoracic Cancers at Massachusetts General Hospital (MGH). He also serves as Director of Targeted Immunotherapy at the Henri and Belinda Termeer Center for Targeted Therapies at MGH and is Co-leader of the Dana-Farber/Harvard Cancer Center Lung Program. Dr. Gainor holds the academic title of Assistant Professor of Medicine at Harvard Medical School. His clinical and research interests focus on thoracic malignancies and immunotherapy.
Disclosures
Grants/Research Support: Takeda
Honoraria/Consulting Fees: AI Proteins, Amgen, Arcus, AstraZeneca, BeiGene, Blueprint Medicines, Bristol-Myers Squibb, Ellipses Pharma, Genentech/Roche, Ironwood Pharmaceuticals, iTeos, Jazz Pharmaceuticals, Karyopharm, Loxo/Lilly, Mariana Oncology (Curie), Merck, Merus Pharmaceuticals, Mirati, Novartis, Nuvalent, Pfizer, Sanofi, Silverback Therapeutics, Takeda, Tempus
Equity/Stock Ownership: AI Proteins
Spouse/Partner Employment: Ironwood Pharmaceuticals
Other Support: AI Proteins (Advisory Board, Consulting, Equity)
Nicolas Girard
Professor of Respiratory Medicine,
Versailles Saint Quentin University, Paris Saclay, Paris, France
Nicolas Girard is a pneumologist specializing in thoracic oncology, for the treatment of patients with lung cancer or rare thoracic cancers. His expertise ranges from the development of perioperative strategies in resectable tumors, to the management of locally-advanced disease and oncogene-addicted tumors, especially EGFR-mutant NSCLC. He is domain leader for rare thoracic cancers for the European Reference Network EURACAN. Nicolas Girard is involved in several clinical and translational research projects aiming at improving the treatment of these cancers. He is also the Head of the Curie-Montsouris Thorax Institute, and Chair of Medical Oncology Department at Institut Curie in Paris. Nicolas Girard co-authored more than 300 articles in peer-reviewed journals.
Disclosures:
Research grants/support from: Abbvie, Amgen, AstraZeneca, Beigene, Boeringer Ingelheim, Bristol Myers Squib, Daiichi-Sankyo, Gilead, Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merck Serono, Merck Sharp & Dohme, Novartis, Sanofi, Sivan.
Consultative services for: Abbvie, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Ipsen, Hoffmann-La Roche, Janssen, LeoPharma, Lilly, Merck Sharpe & Dohme, Mirati, Novartis, Pfizer, Pierre Fabre, Sanofi, Sivan Takeda.
Participation on a data safety monitoring board for Hoffmann-La Roche.
Employment of a family member with AstraZeneca.
Xiuning Le
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
As an Associate Professor and Deputy Section Chief in the Thoracic/Head and Neck department Dr. Le has contributed her knowledge via trials, clinical journals and lectures with focus non-small cell lung cancer with actionable oncogenes.
Dr. Le earned her medical degree from the Peking Union Medical College. She then went on to earn a degree in Biological and Biomedical Sciences at Harvard Medical School in Boston. She completed her internship and residency at The University of Massachusetts Medical Center in Worcester, MA, an additional residency at the University of Texas. Prior to joining the staff at M.D. Anderson, she also completed a fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School. Board certified in both internal medicine and medical oncology, Dr. Le specializes in thoracic, head, and neck oncology.
Dr. Le has led clinical trials resulted in FDA approval of novel targeted therapies in lung cancer. She has published more than 120 articles in the field of lung and head and neck cancer. She was first- or last author of many high-impact papers, including New England Journal of Medicine, Cancer Discovery, Clinical Cancer Research and Journal of Thoracic Oncology.
Dr. Le received the ASCO Young Investigator Award, SU2C-TVF Convergence Program, Claudia Adams Barr for Innovative Cancer Research, ASCO Career Development Award, Paul Calabresi NIH K12 Award, Damon Runyon Award, V Foundation Award, and Sabin Award, and more.
Disclosures:
Consulting/advisory fees: Eli Lilly, EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Regeneron, Boehringer Ingelheim, Hengrui Therapeutics, Bayer, Teligene, Taiho, Daiichi Sankyo, Janssen, Blueprint Medicines, Sensei Biotherapeutics, SystImmune, ArriVent, Abion, and Abbvie.
Research Funding to Institution: Eli Lilly, EMD Serono, ArriVent, Dizal, Teligene, Regeneron, Janssen, ThermoFisher, Takeda, and Boehringer Ingelheim.
Travel support: EMD Serono, Janssen, and Spectrum Pharmaceutics.
Stock options: BlossomHill
Program Director
Fernando Lopez-Rios
Director, Molecular Diagnostics Service, Hospital Universitario 12 de Octubre, Madrid, Spain
Fernando Lopez-Rios has recently joined the Department of Pathology at “12 de Octubre” University Hospital (Madrid) as the Chief of the Molecular Diagnostics Service. He received his medical degree and PhD from the Faculty of Medicine at Autonoma University and Complutense University respectively and completed his residency in Pathology at “12 de Octubre” University Hospital (Madrid). Dr Lopez-Rios has also been the Director of the Therapeutic Targets Laboratory at “HM Hospitales” and a visiting researcher at Memorial Sloan Kettering Cancer Center (USA). His main clinical and research expertise is in cancer biomarker testing, with a special interest in lung cancer and mesothelioma. He is currently a member of the IASLC Pathology Committee.
Disclosures:
Grants/research support: Lilly, Roche, Thermo Fisher Scientific
Honoraria or consultation fees: Lilly, Roche, Thermo Fisher Scientific, Astra Zeneca, Bayer, Takeda, Janssen, MSD, BMS, Pfizer
Caterina Marchiò
Associate Professor of Pathology,
University of Turin, Italy
Dr. Caterina Marchiò is an Experimental Pathologist leading the Research Program of the Pathology Unit at the Candiolo Cancer Institute.
Dr. Marchiò is devoted to deconvoluting the complexity of Pathology to foster precision medicine. She is also actively involved in the standardization of preanalytical conditions of tissue sample management and processing, to guarantee quality of DNA, RNA and antigens.
She has been involved in the ESMO Translational Research and Precision Medicine Working Group and led the consensus recommendation paper on the standard methods to detect NTRK fusions in daily practice and clinical research.
Disclosures:
Honoraria or consultation fees: Bayer, Roche, Daiichi Sankyo, AstraZeneca
Alex Miles
Police Officer and Patient
Alex has worked in law enforcement in the UK for almost 25 years. He is husband to his beautiful wife and father to four wonderful children. He loves exercise and fitness and his hobbies include watching his beloved Tottenham Hotspur when he can. He was diagnosed with lung cancer in 2019, but continues to fight and enjoy life to the full.
Disclosures:
None to declare
Luis Paz-Ares, MD, PhD
Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre
Associate Professor, Universidad Complutense de Madrid
Head, Lung Cancer Unit, Spanish National Cancer Research Center (CNIO)
Dr. Luis Paz-Ares is Chair of the Medical Oncology Department at Hospital Universitario 12 de Octubre and Head of the Lung Cancer Unit at CNIO in Madrid. He also serves as Associate Professor at Universidad Complutense de Madrid and is a member of the Real Academia de Farmacia de Galicia.
He trained in medical oncology in Madrid and Glasgow, and has held leadership roles in oncology departments across Spain. His research focuses on lung cancer and the development of novel therapies, with over 340 publications in leading journals including NEJM, Lancet, and JCO. Dr. Paz-Ares has served on scientific committees for ASCO, ESMO, EORTC, and regulatory agencies including the Spanish Agency of Medicines and the European Medicines Agency. Dr. Paz-Ares is Chief Medical Officer of the Spanish Association Against Cancer (AECC), where he also serves on the Board.
Disclosures
Grants/Research Support (paid to institution): AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme (MSD), Pfizer, Roche
Honoraria/Consulting Fees: AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bayer, BeOne, BeiGene, BMS, Boehringer Ingelheim, Daiichi Sankyo, Gilead, GSK, Janssen, Lilly, Medscape, Merck, Mirati, MSD, Novartis, Pharmamar, Pfizer, Regeneron, Roche/Genentech, Sanofi, Takeda
Speaker’s Bureau Participation: AbbVie, Amgen, AstraZeneca, BeiGene, BMS, Boehringer Ingelheim, Daiichi Sankyo, Lilly, Merck, MSD, Novartis, Pfizer, Pharmamar, Janssen, Regeneron, Roche
Equity/Stock Ownership: Altum Sequencing, Stab Therapeutics
Spouse/Partner Employment: Amgen, Astellas, Crinetics Pharmaceuticals, Esteve, HUTCHMED, Ipsen, ITM, Merck, Novartis, Pfizer, Roche, Sanofi, Servier
Sanjay Popat, FRCP, PhD
Consultant Medical Oncologist
Professor of Thoracic Oncology
Professor Popat is Chair of Thoracic Oncology at The Institute of Cancer Research and Consultant Medical Oncologist at The Royal Marsden Hospital where he is Head of the Lung Unit and Head of the Lung Research programme. He is an internationally recognized expert in the treatment of thoracic malignancies.
His primary research interests include the complexities of cancer genomics, optimization of testing and implementation of genomic testing into routine clinical practice, as well as developing novel drug treatments through clinical trials.
He has published over 300 papers with over 20,000 citations, including influential trial manuscripts in oncogene-addicted NSCLC and mesothelioma, leading to global licensing, reimbursement in multiple territories, and recommendations in international treatment guidelines. He has co-authored European guidelines for the treatment of small cell lung cancer, non-small cell lung cancer, mesothelioma, and ctDNA use.
Nationally, he is founding chair of the British Thoracic Oncology Group (BTOG) Research Group and is immediate past chair of the BTOG Steering Committee and past co-Director for the Cancer division of the UK South London Clinical Research Network. Internationally, he sits on the Foundation Council of the European Thoracic Oncology Platform (ETOP) and holds several roles in the European Society of Medical Oncology (ESMO).
Disclosures
Honoraria or consultation fees: Amgen, Anheart, Arcus Biosciences, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Ellipses, Erasca, Gilead, GlaxoSmithKline, Guardant Health, IO Biotech, Janssen, Lilly, Merck KGaA, Mirati, MSD, Novocure, Novartis, Pfizer, PharmaMar, Pierre Fabre, Roche, Sanofi, Takeda
Lynette M. Sholl, MD
Pathologist, Brigham and Women’s Hospital
Professor of Pathology, Harvard Medical School
Dr. Lynette M. Sholl is a pathologist at Brigham and Women’s Hospital in Boston and Professor of Pathology at Harvard Medical School. She completed her medical school training at Stanford University School of Medicine, an internship in internal medicine at the Hospital of University of Pennsylvania, anatomic pathology residency and fellowship at Brigham and Women’s Hospital, and the molecular genetics pathology fellowship at the Harvard teaching hospitals. Her research interests include predictive tumor characterization and clinical validation of novel molecular and immunohistochemical tests for lung cancers. Dr. Sholl’s responsibilities include serving as the Division Chief for Molecular Diagnostics at Mass General Brigham and as Chief of the Pulmonary Pathology Service at Brigham and Women’s Hospital.
Disclosures
Grants/Research Support: Bristol Myers Squibb, Genentech
Honoraria/Consulting Fees: Genentech, Lilly